| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 47 | 2020 | 1728 | 2.460 |
Why?
|
| Lung | 72 | 2024 | 3559 | 2.100 |
Why?
|
| Occupational Exposure | 7 | 2024 | 255 | 1.840 |
Why?
|
| Coal Mining | 5 | 2024 | 11 | 1.780 |
Why?
|
| Lung Diseases, Interstitial | 23 | 2020 | 508 | 1.380 |
Why?
|
| Pulmonary Artery | 23 | 2020 | 1015 | 1.360 |
Why?
|
| Anthracosis | 2 | 2024 | 4 | 1.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 11 | 2023 | 913 | 1.120 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 11 | 2023 | 505 | 1.070 |
Why?
|
| Pneumoconiosis | 5 | 2024 | 12 | 1.060 |
Why?
|
| Lung Diseases | 10 | 2023 | 701 | 1.000 |
Why?
|
| Emphysema | 5 | 2022 | 107 | 1.000 |
Why?
|
| Bronchiolitis | 4 | 2022 | 81 | 0.990 |
Why?
|
| Pulmonary Fibrosis | 10 | 2013 | 323 | 0.650 |
Why?
|
| Familial Primary Pulmonary Hypertension | 4 | 2016 | 190 | 0.640 |
Why?
|
| Alveolitis, Extrinsic Allergic | 4 | 2020 | 86 | 0.610 |
Why?
|
| Lung Neoplasms | 8 | 2020 | 2177 | 0.560 |
Why?
|
| Neovascularization, Pathologic | 7 | 2019 | 281 | 0.550 |
Why?
|
| Endothelial Cells | 13 | 2020 | 685 | 0.530 |
Why?
|
| Bronchi | 3 | 2016 | 231 | 0.530 |
Why?
|
| Veins | 2 | 2016 | 55 | 0.520 |
Why?
|
| Bronchial Arteries | 1 | 2016 | 11 | 0.520 |
Why?
|
| Apoptosis | 19 | 2020 | 2362 | 0.510 |
Why?
|
| Humans | 132 | 2024 | 114662 | 0.500 |
Why?
|
| Microvessels | 1 | 2016 | 68 | 0.500 |
Why?
|
| Herpesviridae Infections | 6 | 2015 | 138 | 0.480 |
Why?
|
| Military Personnel | 1 | 2022 | 524 | 0.480 |
Why?
|
| Models, Biological | 3 | 2020 | 1620 | 0.450 |
Why?
|
| Middle Aged | 56 | 2024 | 26733 | 0.430 |
Why?
|
| Dust | 5 | 2024 | 84 | 0.430 |
Why?
|
| Immunohistochemistry | 22 | 2019 | 1629 | 0.420 |
Why?
|
| Silicon Dioxide | 5 | 2024 | 88 | 0.420 |
Why?
|
| Fibroblasts | 9 | 2017 | 838 | 0.410 |
Why?
|
| Mucin-5B | 4 | 2019 | 183 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 16 | 2023 | 2285 | 0.370 |
Why?
|
| Male | 73 | 2024 | 55583 | 0.370 |
Why?
|
| Common Variable Immunodeficiency | 4 | 2020 | 24 | 0.360 |
Why?
|
| Cysts | 2 | 2023 | 93 | 0.360 |
Why?
|
| Aged | 39 | 2024 | 19069 | 0.360 |
Why?
|
| Animals | 50 | 2023 | 31698 | 0.350 |
Why?
|
| Adult | 46 | 2024 | 30544 | 0.350 |
Why?
|
| Hypoxia | 8 | 2020 | 957 | 0.340 |
Why?
|
| Herpesvirus 8, Human | 3 | 2005 | 61 | 0.330 |
Why?
|
| Immunosuppressive Agents | 5 | 2020 | 646 | 0.330 |
Why?
|
| Occupational Diseases | 2 | 2023 | 128 | 0.330 |
Why?
|
| Bleomycin | 4 | 2019 | 228 | 0.330 |
Why?
|
| Pulmonary Alveoli | 4 | 2010 | 373 | 0.320 |
Why?
|
| Endothelium, Vascular | 10 | 2012 | 847 | 0.320 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 9 | 2013 | 103 | 0.320 |
Why?
|
| Female | 70 | 2021 | 59493 | 0.320 |
Why?
|
| Virus Diseases | 1 | 2011 | 195 | 0.310 |
Why?
|
| Endothelium | 4 | 2006 | 110 | 0.310 |
Why?
|
| Gammaherpesvirinae | 3 | 2018 | 38 | 0.310 |
Why?
|
| Disease Models, Animal | 15 | 2023 | 3532 | 0.300 |
Why?
|
| Rats | 20 | 2020 | 4958 | 0.290 |
Why?
|
| Biopsy | 15 | 2021 | 1036 | 0.290 |
Why?
|
| Lung Transplantation | 3 | 2022 | 246 | 0.280 |
Why?
|
| Gene Expression Regulation | 8 | 2017 | 2319 | 0.280 |
Why?
|
| Pulmonary Emphysema | 4 | 2013 | 268 | 0.280 |
Why?
|
| Caveolin 1 | 2 | 2006 | 20 | 0.280 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2020 | 74 | 0.270 |
Why?
|
| Caveolin 2 | 1 | 2006 | 3 | 0.270 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2006 | 21 | 0.260 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2006 | 58 | 0.250 |
Why?
|
| Silicosis | 2 | 2023 | 21 | 0.250 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 384 | 0.250 |
Why?
|
| Environmental Exposure | 1 | 2009 | 372 | 0.250 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 282 | 0.240 |
Why?
|
| Respiratory Function Tests | 11 | 2020 | 522 | 0.240 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2020 | 2218 | 0.240 |
Why?
|
| Pyrroles | 6 | 2014 | 181 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 13 | 2013 | 498 | 0.230 |
Why?
|
| Gene Expression | 6 | 2020 | 1421 | 0.230 |
Why?
|
| Mice | 25 | 2023 | 14863 | 0.230 |
Why?
|
| Macrophages, Alveolar | 5 | 2018 | 347 | 0.230 |
Why?
|
| Tissue Banks | 1 | 2004 | 17 | 0.230 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2023 | 23 | 0.220 |
Why?
|
| Diagnosis, Differential | 9 | 2023 | 1342 | 0.220 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2015 | 249 | 0.220 |
Why?
|
| Indoles | 6 | 2014 | 304 | 0.220 |
Why?
|
| Birt-Hogg-Dube Syndrome | 1 | 2023 | 6 | 0.220 |
Why?
|
| Coal | 4 | 2024 | 12 | 0.220 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2022 | 66 | 0.210 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2023 | 27 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2017 | 1139 | 0.210 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2023 | 35 | 0.210 |
Why?
|
| Mycobacterium Infections | 1 | 2023 | 61 | 0.210 |
Why?
|
| Severity of Illness Index | 9 | 2017 | 2538 | 0.210 |
Why?
|
| Interferon-gamma | 5 | 2013 | 719 | 0.210 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2022 | 16 | 0.210 |
Why?
|
| Neprilysin | 3 | 2010 | 47 | 0.200 |
Why?
|
| Rhinitis | 2 | 2017 | 128 | 0.200 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 3 | 2008 | 68 | 0.200 |
Why?
|
| RNA, Messenger | 5 | 2019 | 2552 | 0.200 |
Why?
|
| Skull Base Neoplasms | 1 | 2022 | 24 | 0.200 |
Why?
|
| Mycobacterium | 1 | 2023 | 103 | 0.190 |
Why?
|
| Sinusitis | 2 | 2017 | 174 | 0.190 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2003 | 71 | 0.190 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 1518 | 0.190 |
Why?
|
| Inflammation | 9 | 2022 | 2478 | 0.180 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2021 | 25 | 0.180 |
Why?
|
| Autoimmune Diseases | 2 | 2019 | 382 | 0.180 |
Why?
|
| Prognosis | 8 | 2018 | 3329 | 0.180 |
Why?
|
| Retrospective Studies | 15 | 2024 | 12546 | 0.180 |
Why?
|
| Mice, Knockout | 8 | 2018 | 2568 | 0.180 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 212 | 0.180 |
Why?
|
| Hodgkin Disease | 2 | 2003 | 121 | 0.170 |
Why?
|
| Vaping | 1 | 2021 | 45 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2023 | 242 | 0.170 |
Why?
|
| Inhalation Exposure | 2 | 2018 | 97 | 0.170 |
Why?
|
| Interleukin-18 | 3 | 2013 | 219 | 0.170 |
Why?
|
| Myositis, Inclusion Body | 1 | 2019 | 11 | 0.170 |
Why?
|
| Chronic Disease | 7 | 2020 | 1578 | 0.170 |
Why?
|
| fas Receptor | 3 | 2018 | 91 | 0.160 |
Why?
|
| Virus Activation | 2 | 2018 | 78 | 0.160 |
Why?
|
| Fibrosis | 5 | 2023 | 453 | 0.160 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2019 | 54 | 0.160 |
Why?
|
| Virus Latency | 2 | 2018 | 80 | 0.160 |
Why?
|
| Nestin | 1 | 2019 | 16 | 0.160 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2019 | 26 | 0.160 |
Why?
|
| Microcirculation | 1 | 2019 | 135 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2018 | 7 | 0.160 |
Why?
|
| Cell Line | 10 | 2018 | 2636 | 0.160 |
Why?
|
| Racemases and Epimerases | 1 | 2018 | 11 | 0.160 |
Why?
|
| Pneumonia | 7 | 2009 | 567 | 0.160 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 166 | 0.160 |
Why?
|
| Apolipoprotein A-I | 1 | 2018 | 25 | 0.160 |
Why?
|
| Pulmonary Circulation | 4 | 2009 | 407 | 0.160 |
Why?
|
| Pneumonia, Bacterial | 2 | 2018 | 106 | 0.150 |
Why?
|
| Lung Injury | 1 | 2021 | 197 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2020 | 63 | 0.150 |
Why?
|
| Case-Control Studies | 11 | 2018 | 3003 | 0.150 |
Why?
|
| Genetic Variation | 2 | 2018 | 870 | 0.150 |
Why?
|
| Epoprostenol | 3 | 2012 | 133 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2018 | 11 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2018 | 594 | 0.150 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2009 | 411 | 0.150 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2013 | 235 | 0.150 |
Why?
|
| Endothelial Growth Factors | 4 | 2002 | 50 | 0.150 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2017 | 10 | 0.150 |
Why?
|
| Lymphokines | 4 | 2002 | 111 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2021 | 224 | 0.140 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2018 | 80 | 0.140 |
Why?
|
| Respiratory Mucosa | 4 | 2014 | 251 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2017 | 386 | 0.140 |
Why?
|
| Myofibroblasts | 1 | 2018 | 116 | 0.140 |
Why?
|
| Genotype | 3 | 2018 | 1760 | 0.140 |
Why?
|
| Cell Division | 6 | 2009 | 758 | 0.140 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 333 | 0.140 |
Why?
|
| Complement C3 | 1 | 2018 | 188 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2017 | 80 | 0.140 |
Why?
|
| Genes, Viral | 2 | 2009 | 89 | 0.140 |
Why?
|
| Smoking | 3 | 2017 | 1381 | 0.140 |
Why?
|
| Herpesvirus 4, Human | 1 | 1997 | 125 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 56 | 0.140 |
Why?
|
| Cells, Cultured | 9 | 2020 | 3885 | 0.130 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 129 | 0.130 |
Why?
|
| Thromboplastin | 2 | 2007 | 71 | 0.130 |
Why?
|
| Scleroderma, Systemic | 1 | 1997 | 96 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2013 | 811 | 0.130 |
Why?
|
| Proteins | 3 | 2015 | 908 | 0.130 |
Why?
|
| RNA Stability | 1 | 2017 | 90 | 0.130 |
Why?
|
| Hemangioma, Capillary | 2 | 2006 | 13 | 0.130 |
Why?
|
| Wnt Proteins | 2 | 2015 | 134 | 0.130 |
Why?
|
| Autopsy | 1 | 2016 | 84 | 0.130 |
Why?
|
| Receptors, CXCR4 | 2 | 2014 | 78 | 0.130 |
Why?
|
| Autoantibodies | 3 | 2019 | 1346 | 0.130 |
Why?
|
| Muscle, Smooth | 4 | 2007 | 144 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 445 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 1999 | 551 | 0.130 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2015 | 46 | 0.120 |
Why?
|
| Cell Proliferation | 10 | 2019 | 2186 | 0.120 |
Why?
|
| United States | 5 | 2024 | 12181 | 0.120 |
Why?
|
| Computer Simulation | 1 | 1999 | 872 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 385 | 0.120 |
Why?
|
| Rhadinovirus | 1 | 2015 | 16 | 0.120 |
Why?
|
| Rare Diseases | 3 | 2019 | 89 | 0.120 |
Why?
|
| Transcriptome | 4 | 2023 | 725 | 0.120 |
Why?
|
| NF-kappa B | 3 | 2014 | 641 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2017 | 367 | 0.120 |
Why?
|
| Nitrofurantoin | 1 | 2014 | 7 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2019 | 2968 | 0.120 |
Why?
|
| Bronchopneumonia | 1 | 2014 | 5 | 0.120 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2014 | 13 | 0.120 |
Why?
|
| Cystitis | 1 | 2014 | 20 | 0.120 |
Why?
|
| Glutaredoxins | 1 | 2014 | 11 | 0.110 |
Why?
|
| Autoimmunity | 1 | 2020 | 813 | 0.110 |
Why?
|
| Heterocyclic Compounds | 1 | 2014 | 18 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 344 | 0.110 |
Why?
|
| Airway Remodeling | 2 | 2012 | 57 | 0.110 |
Why?
|
| B-Lymphocytes | 5 | 2012 | 766 | 0.110 |
Why?
|
| Cellular Senescence | 1 | 2015 | 152 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2013 | 217 | 0.110 |
Why?
|
| Virulence Factors | 1 | 2015 | 139 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 4 | 2020 | 448 | 0.110 |
Why?
|
| RNA, Untranslated | 1 | 2015 | 113 | 0.110 |
Why?
|
| CD146 Antigen | 1 | 2013 | 35 | 0.110 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2013 | 25 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 529 | 0.110 |
Why?
|
| beta Catenin | 1 | 2015 | 219 | 0.110 |
Why?
|
| Cryptogenic Organizing Pneumonia | 3 | 2014 | 17 | 0.110 |
Why?
|
| Collagen | 2 | 2012 | 415 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2018 | 338 | 0.100 |
Why?
|
| DNA, Viral | 2 | 2005 | 350 | 0.100 |
Why?
|
| Dyspnea | 3 | 2014 | 211 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2014 | 184 | 0.100 |
Why?
|
| Tyrosine | 2 | 2003 | 214 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 8 | 2015 | 4692 | 0.100 |
Why?
|
| Antigens, CD | 5 | 2009 | 442 | 0.100 |
Why?
|
| Lymphatic Vessels | 1 | 2012 | 54 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 140 | 0.100 |
Why?
|
| Ovalbumin | 1 | 2012 | 161 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2006 | 683 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 295 | 0.100 |
Why?
|
| Young Adult | 6 | 2020 | 10466 | 0.100 |
Why?
|
| Interleukins | 1 | 2013 | 236 | 0.100 |
Why?
|
| Cilia | 1 | 2013 | 162 | 0.100 |
Why?
|
| Simian Immunodeficiency Virus | 3 | 2008 | 70 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1141 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2014 | 298 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 961 | 0.100 |
Why?
|
| Pulmonary Surfactants | 3 | 2018 | 99 | 0.100 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 2 | 2008 | 19 | 0.090 |
Why?
|
| Disease Progression | 6 | 2013 | 2380 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2013 | 1003 | 0.090 |
Why?
|
| Receptors, Growth Factor | 2 | 2002 | 49 | 0.090 |
Why?
|
| T-Lymphocytes | 3 | 2009 | 1737 | 0.090 |
Why?
|
| Biomarkers | 7 | 2019 | 3408 | 0.090 |
Why?
|
| Lymphocytes | 3 | 2009 | 330 | 0.090 |
Why?
|
| Actins | 3 | 2014 | 381 | 0.090 |
Why?
|
| Serpins | 2 | 2015 | 25 | 0.090 |
Why?
|
| Hypertrophy, Right Ventricular | 3 | 2007 | 141 | 0.090 |
Why?
|
| von Willebrand Factor | 3 | 2014 | 56 | 0.090 |
Why?
|
| Hemoptysis | 1 | 2010 | 34 | 0.090 |
Why?
|
| HIV Infections | 3 | 2008 | 2469 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 770 | 0.080 |
Why?
|
| Immunization | 1 | 2012 | 397 | 0.080 |
Why?
|
| Signal Transduction | 8 | 2020 | 4512 | 0.080 |
Why?
|
| Teratoma | 1 | 2010 | 92 | 0.080 |
Why?
|
| Salivary Glands, Minor | 1 | 2009 | 8 | 0.080 |
Why?
|
| Mycophenolic Acid | 2 | 2020 | 77 | 0.080 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2009 | 20 | 0.080 |
Why?
|
| Blotting, Western | 3 | 2010 | 1147 | 0.080 |
Why?
|
| Plasma Cells | 2 | 2009 | 56 | 0.080 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 46 | 0.080 |
Why?
|
| Sjogren's Syndrome | 1 | 2009 | 41 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2009 | 1075 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2002 | 226 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 2085 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2006 | 284 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 182 | 0.080 |
Why?
|
| Bronchoalveolar Lavage Fluid | 5 | 2013 | 590 | 0.080 |
Why?
|
| Scleroderma, Limited | 1 | 2008 | 5 | 0.080 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 6345 | 0.080 |
Why?
|
| Neutrophils | 3 | 2009 | 1176 | 0.080 |
Why?
|
| Nasal Mucosa | 1 | 2009 | 93 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2007 | 1700 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2002 | 61 | 0.080 |
Why?
|
| Specialization | 1 | 2009 | 115 | 0.070 |
Why?
|
| Hemodynamics | 3 | 2012 | 1012 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 25 | 0.070 |
Why?
|
| Cyclins | 2 | 2009 | 78 | 0.070 |
Why?
|
| Mountaineering | 1 | 2008 | 47 | 0.070 |
Why?
|
| Transfection | 4 | 2013 | 866 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 795 | 0.070 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 61 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2007 | 214 | 0.070 |
Why?
|
| Chemotactic Factors | 1 | 2007 | 50 | 0.070 |
Why?
|
| Antihypertensive Agents | 2 | 2012 | 429 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 60 | 0.070 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 110 | 0.070 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 89 | 0.070 |
Why?
|
| Neurosecretory Systems | 2 | 2004 | 32 | 0.070 |
Why?
|
| Acrolein | 1 | 2007 | 23 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2006 | 1016 | 0.070 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 1947 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 249 | 0.070 |
Why?
|
| Photomicrography | 1 | 2006 | 7 | 0.070 |
Why?
|
| Adolescent | 12 | 2020 | 17841 | 0.070 |
Why?
|
| Stress, Mechanical | 2 | 2005 | 445 | 0.070 |
Why?
|
| Gene Products, nef | 1 | 2006 | 12 | 0.070 |
Why?
|
| Angiomatosis | 1 | 2006 | 4 | 0.070 |
Why?
|
| Time Factors | 4 | 2014 | 6114 | 0.070 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2006 | 26 | 0.070 |
Why?
|
| Lymphocytosis | 1 | 2006 | 9 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2012 | 600 | 0.070 |
Why?
|
| Asthma | 3 | 2021 | 2029 | 0.070 |
Why?
|
| Arterioles | 1 | 2006 | 39 | 0.070 |
Why?
|
| Immune System Diseases | 1 | 2006 | 32 | 0.070 |
Why?
|
| Virus Replication | 4 | 2009 | 395 | 0.070 |
Why?
|
| Adenoma | 2 | 2004 | 189 | 0.060 |
Why?
|
| Simvastatin | 1 | 2006 | 59 | 0.060 |
Why?
|
| Leukocyte Common Antigens | 2 | 2014 | 75 | 0.060 |
Why?
|
| Hemangioma | 1 | 2006 | 41 | 0.060 |
Why?
|
| Receptor, Bradykinin B2 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Bronchography | 1 | 2005 | 9 | 0.060 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2005 | 27 | 0.060 |
Why?
|
| Cohort Studies | 6 | 2012 | 4895 | 0.060 |
Why?
|
| Subacute Sclerosing Panencephalitis | 1 | 2005 | 5 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2007 | 273 | 0.060 |
Why?
|
| Capillaries | 1 | 2005 | 91 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2022 | 2128 | 0.060 |
Why?
|
| Calcium Channels, T-Type | 1 | 2005 | 16 | 0.060 |
Why?
|
| Vasculitis | 1 | 2005 | 66 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 140 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2005 | 53 | 0.060 |
Why?
|
| Calcineurin Inhibitors | 1 | 2005 | 58 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2007 | 307 | 0.060 |
Why?
|
| Syndrome | 2 | 2022 | 333 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2006 | 155 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2004 | 27 | 0.060 |
Why?
|
| Sepharose | 1 | 2004 | 31 | 0.060 |
Why?
|
| Lipopolysaccharides | 3 | 2018 | 821 | 0.060 |
Why?
|
| Organ Preservation Solutions | 1 | 2004 | 39 | 0.060 |
Why?
|
| Pulmonary Ventilation | 1 | 2005 | 72 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2014 | 397 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 86 | 0.060 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2004 | 26 | 0.060 |
Why?
|
| Collagen Diseases | 1 | 2004 | 6 | 0.060 |
Why?
|
| Acromegaly | 1 | 2004 | 12 | 0.060 |
Why?
|
| Organ Preservation | 1 | 2004 | 64 | 0.060 |
Why?
|
| HIV-1 | 2 | 2008 | 768 | 0.060 |
Why?
|
| Silicates | 1 | 2024 | 11 | 0.060 |
Why?
|
| Chemokine CXCL12 | 2 | 2019 | 74 | 0.060 |
Why?
|
| Sirolimus | 1 | 2005 | 181 | 0.060 |
Why?
|
| Granuloma | 1 | 2004 | 83 | 0.060 |
Why?
|
| Nerve Growth Factors | 1 | 2004 | 71 | 0.060 |
Why?
|
| Eye Proteins | 1 | 2004 | 70 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2023 | 29 | 0.060 |
Why?
|
| Guanosine | 1 | 2003 | 39 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2007 | 497 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2005 | 236 | 0.060 |
Why?
|
| Castleman Disease | 1 | 2003 | 12 | 0.060 |
Why?
|
| Caspases | 3 | 2014 | 245 | 0.060 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2004 | 128 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2024 | 192 | 0.060 |
Why?
|
| Genetic Techniques | 1 | 2004 | 58 | 0.060 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2003 | 48 | 0.050 |
Why?
|
| Communication | 1 | 2009 | 744 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 158 | 0.050 |
Why?
|
| Mutation | 2 | 2023 | 3345 | 0.050 |
Why?
|
| Carmustine | 1 | 2003 | 47 | 0.050 |
Why?
|
| Pneumonectomy | 3 | 2010 | 125 | 0.050 |
Why?
|
| Transplantation Chimera | 1 | 2003 | 51 | 0.050 |
Why?
|
| Siderosis | 1 | 2002 | 2 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 959 | 0.050 |
Why?
|
| Plague | 1 | 2003 | 42 | 0.050 |
Why?
|
| Capillary Permeability | 2 | 2013 | 139 | 0.050 |
Why?
|
| Macaca | 3 | 2008 | 50 | 0.050 |
Why?
|
| Occupations | 1 | 2022 | 36 | 0.050 |
Why?
|
| Child | 7 | 2009 | 18412 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2004 | 286 | 0.050 |
Why?
|
| Interleukin-6 | 3 | 2014 | 676 | 0.050 |
Why?
|
| Sudden Infant Death | 1 | 2002 | 24 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2003 | 95 | 0.050 |
Why?
|
| Clone Cells | 2 | 2020 | 247 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 373 | 0.050 |
Why?
|
| Biopolymers | 1 | 2022 | 26 | 0.050 |
Why?
|
| Skull Base | 1 | 2022 | 39 | 0.050 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2022 | 28 | 0.050 |
Why?
|
| Hyperplasia | 4 | 2004 | 163 | 0.050 |
Why?
|
| Chinchilla | 1 | 2022 | 37 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 506 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2003 | 218 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2003 | 1862 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 270 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 209 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 192 | 0.050 |
Why?
|
| Bronchoscopy | 3 | 2010 | 245 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2003 | 281 | 0.050 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2002 | 112 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2004 | 230 | 0.050 |
Why?
|
| Brain | 2 | 2005 | 2371 | 0.050 |
Why?
|
| Stem Cells | 2 | 2003 | 546 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 535 | 0.050 |
Why?
|
| Radiography | 3 | 2012 | 812 | 0.050 |
Why?
|
| Mycobacterium avium Complex | 1 | 2021 | 92 | 0.050 |
Why?
|
| Lung Volume Measurements | 1 | 2001 | 45 | 0.050 |
Why?
|
| E-Selectin | 2 | 2015 | 53 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2008 | 157 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 723 | 0.040 |
Why?
|
| Risk Factors | 2 | 2011 | 8632 | 0.040 |
Why?
|
| Reference Values | 2 | 2018 | 743 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2002 | 304 | 0.040 |
Why?
|
| Azathioprine | 1 | 2020 | 49 | 0.040 |
Why?
|
| Thrombosis | 1 | 2003 | 298 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2013 | 86 | 0.040 |
Why?
|
| Sulfhydryl Compounds | 1 | 2022 | 177 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2014 | 1226 | 0.040 |
Why?
|
| Interleukin-8 | 2 | 2013 | 237 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2018 | 1230 | 0.040 |
Why?
|
| Prevalence | 2 | 2022 | 2251 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2000 | 83 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 119 | 0.040 |
Why?
|
| Keratin-15 | 1 | 2019 | 12 | 0.040 |
Why?
|
| Pulmonary Edema | 2 | 2013 | 115 | 0.040 |
Why?
|
| Endoscopy | 1 | 2022 | 246 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 1143 | 0.040 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 71 | 0.040 |
Why?
|
| Rituximab | 1 | 2020 | 150 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2000 | 76 | 0.040 |
Why?
|
| Mast Cells | 1 | 2000 | 116 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 1131 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1999 | 69 | 0.040 |
Why?
|
| Colloids | 1 | 2019 | 56 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 2710 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1796 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2009 | 9114 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2005 | 665 | 0.040 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2020 | 132 | 0.040 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 1999 | 57 | 0.040 |
Why?
|
| Observer Variation | 2 | 2012 | 295 | 0.040 |
Why?
|
| Weight Loss | 2 | 2014 | 642 | 0.040 |
Why?
|
| Mesoderm | 1 | 2020 | 138 | 0.040 |
Why?
|
| Caspase Inhibitors | 2 | 2012 | 78 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2009 | 1211 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 923 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 153 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1999 | 108 | 0.040 |
Why?
|
| Cell Separation | 1 | 2020 | 291 | 0.040 |
Why?
|
| Neoplasms | 2 | 2009 | 2097 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 1879 | 0.040 |
Why?
|
| CD13 Antigens | 1 | 1998 | 5 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2018 | 66 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2018 | 66 | 0.040 |
Why?
|
| Prednisone | 1 | 2019 | 229 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 1037 | 0.040 |
Why?
|
| Food Additives | 1 | 2018 | 7 | 0.040 |
Why?
|
| Radiography, Thoracic | 2 | 2010 | 150 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 4411 | 0.040 |
Why?
|
| Bronchioles | 1 | 2018 | 22 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1999 | 174 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2013 | 119 | 0.040 |
Why?
|
| Cough | 2 | 2014 | 107 | 0.040 |
Why?
|
| Food Industry | 1 | 2018 | 14 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 51 | 0.040 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2019 | 139 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2020 | 309 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 2014 | 292 | 0.040 |
Why?
|
| Epithelial Cells | 3 | 2009 | 950 | 0.040 |
Why?
|
| Macrophages | 3 | 2013 | 1261 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 740 | 0.040 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 1998 | 45 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 61 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2003 | 520 | 0.040 |
Why?
|
| Mucin-1 | 1 | 1997 | 18 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2003 | 1076 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2001 | 554 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 718 | 0.040 |
Why?
|
| Cystic Fibrosis | 2 | 2008 | 955 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 687 | 0.040 |
Why?
|
| Kenya | 1 | 1997 | 96 | 0.040 |
Why?
|
| Japan | 1 | 2017 | 86 | 0.030 |
Why?
|
| Factor VIII | 1 | 1997 | 53 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 750 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1997 | 53 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 299 | 0.030 |
Why?
|
| CD3 Complex | 1 | 1997 | 92 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 1997 | 103 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2019 | 270 | 0.030 |
Why?
|
| Rats, Nude | 2 | 2007 | 26 | 0.030 |
Why?
|
| Cholesterol | 1 | 2018 | 367 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2005 | 1040 | 0.030 |
Why?
|
| Treatment Outcome | 4 | 2019 | 9088 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2020 | 1083 | 0.030 |
Why?
|
| ADAMTS9 Protein | 1 | 2015 | 6 | 0.030 |
Why?
|
| Serpin E2 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2015 | 8 | 0.030 |
Why?
|
| ADAMTS4 Protein | 1 | 2015 | 15 | 0.030 |
Why?
|
| Arteries | 2 | 2010 | 247 | 0.030 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2015 | 29 | 0.030 |
Why?
|
| Hypertension | 1 | 2003 | 1056 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2019 | 574 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2015 | 58 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 1998 | 477 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2003 | 1528 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1842 | 0.030 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2015 | 18 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2008 | 785 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2006 | 6219 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 385 | 0.030 |
Why?
|
| Thiocarbamates | 1 | 2014 | 6 | 0.030 |
Why?
|
| Iloprost | 1 | 2015 | 46 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2006 | 235 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2000 | 442 | 0.030 |
Why?
|
| Cannabis | 1 | 2021 | 384 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 2014 | 55 | 0.030 |
Why?
|
| Benzylamines | 1 | 2014 | 39 | 0.030 |
Why?
|
| Endostatins | 1 | 2013 | 9 | 0.030 |
Why?
|
| Virulence | 1 | 2015 | 227 | 0.030 |
Why?
|
| Epithelium | 2 | 2007 | 295 | 0.030 |
Why?
|
| Activins | 1 | 2013 | 26 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2014 | 40 | 0.030 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2013 | 20 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2014 | 58 | 0.030 |
Why?
|
| Forced Expiratory Volume | 2 | 2007 | 475 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1998 | 695 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2018 | 532 | 0.030 |
Why?
|
| RNA | 2 | 2013 | 809 | 0.030 |
Why?
|
| Nitrogen Oxides | 1 | 2013 | 47 | 0.030 |
Why?
|
| Mortality, Premature | 1 | 2013 | 11 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2013 | 45 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2015 | 356 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 89 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2005 | 184 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2012 | 12 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 66 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.030 |
Why?
|
| Lymphangiogenesis | 1 | 2012 | 24 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 304 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 259 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2012 | 49 | 0.030 |
Why?
|
| Antilymphocyte Serum | 1 | 2012 | 60 | 0.030 |
Why?
|
| Asparagine | 1 | 2012 | 29 | 0.030 |
Why?
|
| Glutathione | 1 | 2014 | 293 | 0.030 |
Why?
|
| Nuclear Proteins | 2 | 2008 | 591 | 0.030 |
Why?
|
| Fatigue | 1 | 2014 | 294 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 217 | 0.030 |
Why?
|
| Cardiomegaly | 1 | 2013 | 157 | 0.020 |
Why?
|
| Tobacco Products | 1 | 2013 | 98 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1998 | 1018 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 322 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 433 | 0.020 |
Why?
|
| Survival Rate | 2 | 2007 | 1644 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 351 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 337 | 0.020 |
Why?
|
| Cytokines | 2 | 2014 | 1840 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2013 | 253 | 0.020 |
Why?
|
| Phenotype | 2 | 2013 | 2796 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 923 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1167 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 398 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2012 | 317 | 0.020 |
Why?
|
| Chest Pain | 1 | 2010 | 81 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2010 | 255 | 0.020 |
Why?
|
| Maxillary Sinus | 1 | 2009 | 11 | 0.020 |
Why?
|
| Elastin | 1 | 2009 | 78 | 0.020 |
Why?
|
| Eisenmenger Complex | 1 | 2008 | 10 | 0.020 |
Why?
|
| Myoblasts | 1 | 2009 | 76 | 0.020 |
Why?
|
| Peroxidase | 1 | 2009 | 163 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2009 | 134 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2008 | 16 | 0.020 |
Why?
|
| Natural Killer T-Cells | 1 | 2009 | 63 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1569 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2008 | 131 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2005 | 1538 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 993 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2008 | 84 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 510 | 0.020 |
Why?
|
| Infant | 3 | 2009 | 7961 | 0.020 |
Why?
|
| Monocrotaline | 1 | 2007 | 26 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2010 | 554 | 0.020 |
Why?
|
| Cell Transdifferentiation | 1 | 2007 | 31 | 0.020 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2007 | 60 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2008 | 177 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2008 | 187 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 134 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 117 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 195 | 0.020 |
Why?
|
| Angiography | 1 | 2007 | 174 | 0.020 |
Why?
|
| Receptors, Epoprostenol | 1 | 2006 | 6 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2007 | 283 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2007 | 255 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 493 | 0.020 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2005 | 8 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2006 | 105 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2005 | 78 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2005 | 4 | 0.020 |
Why?
|
| Measles virus | 1 | 2005 | 10 | 0.020 |
Why?
|
| Microdissection | 1 | 2005 | 15 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2006 | 316 | 0.020 |
Why?
|
| Cycloheximide | 1 | 2005 | 54 | 0.020 |
Why?
|
| Mibefradil | 1 | 2005 | 6 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2005 | 35 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2005 | 38 | 0.020 |
Why?
|
| Diltiazem | 1 | 2005 | 23 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 641 | 0.020 |
Why?
|
| Shear Strength | 1 | 2005 | 65 | 0.020 |
Why?
|
| Pleura | 1 | 2004 | 18 | 0.020 |
Why?
|
| Glutaral | 1 | 2004 | 14 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2004 | 46 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2005 | 176 | 0.010 |
Why?
|
| Genome, Viral | 1 | 2005 | 118 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2005 | 122 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2005 | 176 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2005 | 283 | 0.010 |
Why?
|
| Lasers | 1 | 2005 | 121 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 342 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2005 | 122 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 296 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 144 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 109 | 0.010 |
Why?
|
| Injections | 1 | 2004 | 159 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 951 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1121 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 289 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 435 | 0.010 |
Why?
|
| Arachidonic Acids | 1 | 2003 | 56 | 0.010 |
Why?
|
| Blood Circulation | 1 | 2003 | 36 | 0.010 |
Why?
|
| CD36 Antigens | 1 | 2003 | 37 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2003 | 30 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2007 | 680 | 0.010 |
Why?
|
| Anthrax | 1 | 2003 | 8 | 0.010 |
Why?
|
| Homeostasis | 1 | 2007 | 573 | 0.010 |
Why?
|
| Yersinia pestis | 1 | 2003 | 34 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2003 | 94 | 0.010 |
Why?
|
| Blood | 1 | 2003 | 96 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2007 | 374 | 0.010 |
Why?
|
| Cell Movement | 1 | 2007 | 868 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 68 | 0.010 |
Why?
|
| Forensic Medicine | 1 | 2002 | 16 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 367 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 430 | 0.010 |
Why?
|
| Pituitary Neoplasms | 1 | 2004 | 157 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2003 | 274 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 84 | 0.010 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2002 | 29 | 0.010 |
Why?
|
| Oxygen | 1 | 2007 | 854 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2002 | 25 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 61 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 64 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2005 | 513 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 309 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2003 | 305 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1313 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2003 | 173 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 447 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 640 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2005 | 349 | 0.010 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Proteolipids | 1 | 2001 | 28 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 119 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2002 | 413 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 419 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2001 | 55 | 0.010 |
Why?
|
| Polymers | 1 | 2004 | 448 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2001 | 57 | 0.010 |
Why?
|
| Cyanosis | 1 | 2000 | 15 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2005 | 823 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2001 | 123 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 2000 | 10 | 0.010 |
Why?
|
| Transgenes | 1 | 2001 | 170 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 2000 | 33 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 2003 | 534 | 0.010 |
Why?
|
| CREST Syndrome | 1 | 1999 | 6 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 280 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 157 | 0.010 |
Why?
|
| Cysteine | 1 | 2000 | 171 | 0.010 |
Why?
|
| Cause of Death | 1 | 2000 | 361 | 0.010 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 1998 | 5 | 0.010 |
Why?
|
| Acute Disease | 1 | 2000 | 911 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1998 | 109 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2763 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2000 | 221 | 0.010 |
Why?
|
| Recurrence | 1 | 2000 | 935 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 966 | 0.010 |
Why?
|
| Sepsis | 1 | 2003 | 509 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1999 | 227 | 0.010 |
Why?
|
| Altitude | 1 | 2001 | 432 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2000 | 529 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 1998 | 131 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 1618 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1355 | 0.010 |
Why?
|
| Age Factors | 1 | 2001 | 2894 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 1999 | 671 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 5045 | 0.010 |
Why?
|
| DNA | 1 | 1998 | 1352 | 0.010 |
Why?
|